EP Patent

EP4219449A2 — Substituted indole derivatives and methods of preparation thereof

Assigned to University of Michigan System · Expires 2023-08-02 · 3y expired

What this patent protects

The present disclosure provides methods of inhibiting the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The methods are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependant on activity of MLL1, MLL2, MLL fusion proteins, a…

USPTO Abstract

The present disclosure provides methods of inhibiting the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The methods are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependant on activity of MLL1, MLL2, MLL fusion proteins, and/or menin. Compositions for use in these methods are also provided.

Drugs covered by this patent

Patent Metadata

Patent number
EP4219449A2
Jurisdiction
EP
Classification
—
Expires
2023-08-02
Drug substance claim
No
Drug product claim
No
Assignee
University of Michigan System
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.